VaxigripTetra Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

The vaccine, after shaking gently, is a colourless opalescent liquid.
Influenza virus (inactivated, split) of the following strains*: A/Victoria/4897/2022 (H1N1) pdm09-like strain (A/Victoria/4897/2022, IVR-238) 15 micrograms HA**.
A/Thailand/8/2022 (H3N2)-like strain (A/California/122/2022, SAN-022) 15 micrograms HA**.
B/Austria/1359417/2021-like strain (B/Michigan/01/2021, wild type) 15 micrograms HA**.
B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, wild type) 15 micrograms HA**.
For one 0.5 mL dose.
* Propagated in fertilised hens' eggs from healthy chicken flocks.
** haemagglutinin.
This vaccine complies with the WHO recommendations (Northern Hemisphere) for the 2024/2025 season.
VaxigripTetra may contain traces of eggs, such as ovalbumin, and of neomycin, formaldehyde and octoxinol-9, which are used during the manufacturing process (see Contraindications).
Excipients/Inactive Ingredients: Buffer Solution: Sodium chloride, Potassium chloride, Disodium phosphate dihydrate, Potassium dihydrogen phosphate, Water for injections.

VaxigripTetra Description

influenza vaccine

Manufacturer:

Sanofi

Distributor:

Zuellig Pharma